Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III study of AJG511 in patients with active ulcerative colitis

Next Previous
X
Search
Trial Profile

Phase III study of AJG511 in patients with active ulcerative colitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Sponsors EA Pharma

    • Most Recent Events

    • 27 Sep 2017 Primary endpoint (Mucosal healing rates) has been met, according to a Kissei Pharmaceutical media release.
    • 27 Sep 2017 According to a Kessei Pharmaceuticals media release, EA Pharma has obtained marketing approval for "RECTABUL 2 mg Rectal Foam 14 Doses" for the treatment of ulcerative colitis in Japan. The approval was based on data from this trial.
    • 28 Oct 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top